CAPRICOR THERAPEUTICS INC

Capricor Therapeutics’ shares rise 4.25 % to $5.92, a brief upside in a volatile biopharma sector—investors weigh long‑term milestones against current price.

Capricor Therapeutics slumps 11% as investors question its DMD pipeline, trading near $6 versus a $21 200‑day SMA, risking further decline.